nach oben

Intensive Care Medicine

Erschienen in:

01.01.2012 | Review

Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis

verfasst von: Angelo Polito, Emilio Parisini, Zaccaria Ricci, Sergio Picardo, Djillali Annane

Erschienen in: Intensive Care Medicine | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To examine the benefits and risks of vasopressin or its analog terlipressin for patients with vasodilatory shock.

Data source

We searched the CENTRAL, MEDLINE, EMBASE, and LILACS databases (up to March 2011) as well as reference lists of articles and proceedings of major meetings; we also contacted trial authors. We considered randomized and quasirandomized trials of vasopressin or terlipressin versus placebo or supportive treatment in adult and pediatric patients with vasodilatory shock. The primary outcome for this review was short-term all-cause mortality.

Study selection

We identified 10 randomized trials (1,134 patients). Six studies were considered for the main analysis on mortality in adults.

Data extraction and synthesis

The crude short-term mortality was 206 of 512 (40.2%) in vasopressin/terlipressin-treated patients and 198 of 461 (42.9%) in controls [six trials, risk ratio (RR) = 0.91; 95% confidence interval (CI) 0.79–1.05; P = 0.21; I ² = 0%]. There were 49 of 463 (10.6%) patients with serious adverse events in the vasopressin/terlipressin arm and 51 of 431 (11.8%) in the control arm (four trials, RR = 0.90; 95% CI 0.49–1.67; P = 0.75; I ² = 26%). Metaregression analysis showed negative correlation between vasopressin dose and norepinephrine dose (P = 0.03).

Conclusions

Overall, use of vasopressin or terlipressin did not produce any survival benefit in the short term in patients with vasodilatory shock. Physicians may value the sparing effects of vasopressin/terlipressin on norepinephrine requirement given its apparent safe profile.

Nur mit Berechtigung zugänglich

Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588–595PubMedCrossRef

Annane D, Aegerter P, Jars-Guincestre MC, Guidet B (2003) Current epidemiology of septic shock: the CUB-Rea network. Am J Respir Crit Care Med 168:165–172PubMedCrossRef

Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296–327PubMedCrossRef

Antonelli M, Azoulay E, Bonten M, Chastre J, Citerio G, Conti G, De Backer D, Lemaire F, Gerlach H, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Pugin J, Wernerman J, Zhang H (2010) Year in review in intensive care medicine 2009:II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching. Intensive Care Med 36:412–427PubMedCrossRef

Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125PubMed

Mutlu GM, Factor P (2004) Role of vasopressin in the management of septic shock. Intensive Care Med 30:1276–1291PubMed

Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758PubMedCrossRef

Dunser MW, Hasibeder WR, Wenzel V, Schwarz S, Ulmer H, Knotzer H, Pajk W, Friesenecker BE, Mayr AJ (2004) Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 32:1266–1271PubMedCrossRef

Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319PubMedCrossRef

10.

Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421PubMedCrossRef

11.

Landry DW, Levin HR, Gallant EM, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282PubMedCrossRef

12.

Asfar P, De Backer D, Meier-Hellmann A, Radermacher P, Sakka SG (2004) Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock. Crit Care 8:170–179PubMedCrossRef

13.

Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A (2003) High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31:2646–2650PubMedCrossRef

14.

Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E (2003) The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 97:1756–1763PubMedCrossRef

15.

Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887PubMedCrossRef

16.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCrossRef

17.

Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M, Guyatt GH (2001) Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 285:2000–2003PubMedCrossRef

18.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef

19.

RM (RevMan) (2008) Version 5.0 Nordic Cochrane center. Cochrane collaboration, Copenhagen, Denmark

20.

Borenstein MHL, Higgins J, Rothstein H (2005) Comprehensive meta-analysis version 2. Biostat, Englewood

21.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

22.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRef

23.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRef

24.

Choong K, Bohn D, Fraser DD, Gaboury I, Hutchison JS, Joffe AR, Litalien C, Menon K, McNamara P, Ward RE (2009) Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. Am J Respir Crit Care Med 180:632–639PubMedCrossRef

25.

Lauzier F, Levy B, Lamarre P, Lesur O (2006) Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 32:1782–1789PubMedCrossRef

26.

Malay MB, Ashton RC, Jr., Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699-703; discussion 703-695

27.

Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582PubMedCrossRef

28.

Albanese J, Leone M, Delmas A, Martin C (2005) Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897–1902PubMedCrossRef

29.

Morelli A, Ertmer C, Lange M, Dunser M, Rehberg S, Van Aken H, Pietropaoli P, Westphal M (2008) Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 100:494–503PubMedCrossRef

30.

Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Bachetoni A, D’Alessandro M, Van Aken H, Pietropaoli P, Westphal M (2009) Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 13:R130PubMedCrossRef

31.

Yildizdas D, Yapicioglu H, Celik U, Sertdemir Y, Alhan E (2008) Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Med 34:511–517PubMedCrossRef

32.

Ceneviva G, Paschall JA, Maffei F, Carcillo JA (1998) Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 102:e19PubMedCrossRef

33.

Higgins JPT GS (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. (updated March 2011). The Cochrane collaboration, 2011. Available from http:\\www.cochrane-handbook.org. In: Editor (eds.) Book Cochrane handbook for systematic reviews of interventions version 5.1.0. (updated March 2011). The Cochrane collaboration, 2011. Available from http:\\www.cochrane-handbook.org

34.

Holmes CL, Patel BM, Russell JA, Walley KR (2001) Physiology of vasopressin relevant to management of septic shock. Chest 120:989–1002PubMedCrossRef

Titel: Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis
verfasst von: Angelo Polito
Emilio Parisini
Zaccaria Ricci
Sergio Picardo
Djillali Annane
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Intensive Care Medicine / Ausgabe 1/2012
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-011-2407-x

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis

Abstract

Objective

Data source

Study selection

Data extraction and synthesis

Conclusions

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Abstract

Objective

Data source

Study selection

Data extraction and synthesis

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Arterial oxygen tension and mortality in mechanically ventilated patients

Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients

Early detection of deteriorating ventilation by monitoring bilateral chest wall dynamics in the rabbit

Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy

Early detection of deteriorating ventilation: prevention is better than cure!

Erratum to: Effects of expiratory tracheal gas insufflation in patients with severe head trauma and acute lung injury

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS